The results were presented during a late-breaking clinical trials session at the European Renal Association (ERA) Congress 1. The study also showed atrasentan has a favorable safety profile consistent with previously reported data 1,9. Proteinuria reduction is a recognized surrogate marker correlating with delaying progression to kidney failure and has been used as an endpoint in IgAN clinical trials to support accelerated regulatory approvals 10. US FDA submission for atrasentan in IgAN is on track for the first half of 2024.